Eton Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
ETON$64.35+14.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| For the years ended | |||
|---|---|---|---|
| December 31, | December 31, | December 31, | |
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(3,823) | $(936) | $(9,021) |
| Adjustments to reconcile net loss to net cash from operating activities: | |||
| Stock-based compensation | 3,165 | 3,137 | 4,218 |
| Depreciation and amortization | 1,146 | 901 | 1,774 |
| Non-cash lease expense | 70 | 67 | 62 |
| Debt discount amortization | 1,109 | 117 | 127 |
| Changes in operating assets and liabilities, net of impact of business acquisition: | |||
| Accounts receivable | (3,118) | (1,559) | 3,619 |
| Inventories | (1,310) | (354) | (7) |
| Prepaid expenses and other assets | (3,349) | 94 | 1,840 |
| Accounts payable | 2,318 | 53 | (8) |
| Accrued Medicaid rebates | 3,239 | 2,818 | 768 |
| Accrued liabilities | 1,484 | 2,477 | 1,449 |
| Other non-current assets and liabilities | 38 | — | — |
| Net cash from operating activities | 969 | 6,815 | 4,821 |
| Cash from investing activities | |||
| Purchases of property and equipment | (26) | — | (38) |
| Acquisition of business | (30,000) | — | — |
| Purchase of product licensing rights | (9,988) | (775) | (2,750) |
| Net cash from investing activities | (40,014) | (775) | (2,788) |
| Cash flows from financing activities | |||
| Net proceeds from the issuance of long-term debt | 25,309 | — | — |
| Repayment of long-term debt | (1,155) | (1,155) | (385) |
| Common stock issued in private placement offering | 7,000 | — | — |
| Proceeds from stock option exercises | 1,191 | 149 | 35 |
| Payment of tax withholding related to net share settlement of stock option exercises | — | (180) | — |
| Employee stock purchase plan | 248 | 229 | 171 |
| Stock warrant exercises | — | — | 45 |
| Net cash from financing activities | 32,593 | (957) | (134) |
| Change in cash and cash equivalents | (6,452) | 5,083 | 1,899 |
| Cash and cash equivalents at beginning of year | 21,388 | 16,305 | 14,406 |
| Cash and cash equivalents at end of year | $14,936 | $21,388 | $16,305 |
| Supplemental disclosures of cash flow information | |||
| Cash paid for interest | $665 | $842 | $730 |
| Cash paid for income taxes | $82 | $247 | $— |
| Supplemental disclosures of non-cash investing and financing activities: | |||
| Debt issuance costs | $386 | $— | $— |
| Fair value of warrants issued in connection with debt agreement | $1,170 | $— | $— |
| Adjustment of operating lease right-of-use assets and liabilities due to tenant allowance | $— | $29 | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $219 | $— | $188 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.